To include your compound in the COVID-19 Resource Center, submit it here.

Nektar gains on NKTR-214/Opdivo combo data

Nektar Therapeutics (NASDAQ:NKTR) gained $4.60 (14%) to $37.10 on Monday after reporting interim response data from the dose-escalation Phase Ib portion of the Phase Ib/II PIVOT-02 trial evaluating NKTR-214

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE